Statistical Analysis Plan for the SANO-trial: Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Active Surveillance for Oesophageal Cancer
NCT05953181 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 776
Last updated 2024-09-19
Summary
An active surveillance approach is proposed after completion of neoadjuvant chemoradiotherapy (nCRT) for carcinoma of the oesophagus. In this SANO (i.e. Surgery As Needed for Oesophageal cancer) approach, surgical resection is offered only to patients in whom a locoregional regrowth is highly suspected or proven, without distant dissemination. Such an organ-preserving strategy can have great advantages, but is only justified if long-term survival is non-inferior to that of the current standard trimodality approach comprising neoadjuvant chemoradiotherapy followed by standard surgery. The aim of this study is to assess the (cost-)effectiveness (including non-financial costs and survival) of active surveillance for patients with squamous cell- or adenocarcinoma of the oesophagus or oesophago-gastric junction.
Conditions
- Esophageal Cancer
- Active Surveillance
- Neoadjuvant Chemoradiotherapy
- Surgical Oncology
Interventions
- PROCEDURE
-
Active surveillance
Patients enrolled in the active surveillance arm will undergo diagnostic evaluations every 3 months in the first year after completion of neoadjuvant treatment, every 4 months in the second year, every 6 months in the third year and yearly in the 4th and 5th year of follow up, or when symptoms or results of any diagnostic test require shorter assessment intervals. In the active surveillance arm, surgical resection will be offered only to those patients, in whom a locoregional regrowth is highly suspected or proven, without any signs of distant dissemination.
Sponsors & Collaborators
- lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 99 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-11-01
- Primary Completion
- 2023-06-01
- Completion
- 2026-06-01
Countries
- Netherlands
Study Locations
More Related Trials
-
Surgery With or Without Radiation Therapy and Chemotherapy in Treating Patients With Esophageal Cancer
NCT00047112 ·Status: COMPLETED ·Phase: PHASE3
-
RCT on the Combined Modality Treatment of Squamous Cell Carcinoma of the Esophagus
NCT00559351 ·Status: TERMINATED ·Phase: PHASE3
-
Chemoradiation and Panitumumab for Esophageal Cancer
NCT01077999 ·Status: COMPLETED ·Phase: PHASE2
-
Surgery With or Without Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus
NCT00003118 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison of Systematic Surgery Versus Surveillance and Rescue Surgery in Operable Oesophageal Cancer With a Complete Clinical Response to Radiochemotherapy
NCT02551458 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Preoperative Image-guided Identification of Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer
NCT03474341 ·Status: UNKNOWN
-
Patient-reported Outcomes in Preoperative Immunochemotherapy/Radiotherapy-treated Esophageal Cancer Patients
NCT05596890 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study Involving Neoadjuvant Chemoradiotherapy with Hypofractionated Radiotherapy in Patients with Esophageal and Gastroesophageal Junction Adenocarcinoma
NCT05370144 ·Status: RECRUITING ·Phase: NA
-
Anlotinib for Esophageal Cancer (AFEC)
NCT04966611 ·Status: UNKNOWN
-
Chemoradiotherapy Versus Esophagectomy After Endoscopic Resection for Superficial Esophageal Squamous Cell Carcinoma
NCT03306901 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Neoadjuvant CRT Combined With Camrelizumab and Nimotuzumab for Initially Inoperable Patients With Esophageal Carcinoma
NCT05355168 ·Status: COMPLETED ·Phase: PHASE2
-
Timing of Resective Surgery After Neoadjuvant Chemoradiotherapy in Esophageal Cancer
NCT02415101 ·Status: COMPLETED ·Phase: NA
-
Oxaliplatin-Based Chemotherapy and Chemoradiotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Carcinoma
NCT00525915 ·Status: COMPLETED ·Phase: PHASE2
-
Oxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Before Surgery and Erlotinib Hydrochloride After Surgery in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
NCT01561014 ·Status: COMPLETED ·Phase: PHASE1
-
Radiation Therapy and Combination Chemotherapy With or Without Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed By Surgery
NCT00416858 ·Status: COMPLETED ·Phase: PHASE3
-
Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy(nCT) in the Treatment of Esophageal Squamous Cell Carcinoma
NCT07312578 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE2
-
Timing of Minimally Invasive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma
NCT07000253 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Total Neoadjuvant Therapy for Lymph Node-positive Adenocarcinoma of the OESophagus and Oesophagogastric Junction
NCT06161818 ·Status: RECRUITING ·Phase: PHASE2
-
Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma
NCT05937438 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Weekly Cisplatin/Irinotecan and Radiotherapy in Patients With Locally Advanced Esophageal Cancer: Phase II Trial
NCT00213486 ·Status: COMPLETED ·Phase: PHASE2
-
Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Cancer: ESWN 01 Trial
NCT02319187 ·Status: UNKNOWN ·Phase: PHASE3
-
Chemotherapy Induction and Chemoradiotherapy in Patients With Esophageal Carcinoma
NCT00735345 ·Status: TERMINATED ·Phase: PHASE2
-
Neoadjuvant Chemotherapy Followed by Preoperative Chemoradiation in Resectable Squamous-cell Esophageal Cancer
NCT03579004 ·Status: UNKNOWN ·Phase: PHASE2
-
An Open-label, Single-center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer
NCT00561197 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Feasibility Study of Chemoradiation, TRAstuzumab and Pertuzumab in Resectable HER2+ Esophageal Carcinoma
NCT02120911 ·Status: COMPLETED ·Phase: PHASE1/PHASE2